Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 16, 2015

View Archived Issues

Nucleic acid antibody prophylaxis as an antiviral immunotherapy for dengue

FDA OOPD awards grant to support development of ADXS-HPV in throat cancer

PeptiDream and Sanofi establish peptide discovery collaboration

RaQualia selects RQ-00433412 for preclinical development in cancer cachexia

STAT2 regulates mitochondrial fission

Baxalta files for U.S. approval of 20% immunoglobulin subcutaneous

XenoPort reports phase II study data for XP-23829

P2X7R antagonist reduces neuronal death in epilepsy model

Amicus Therapeutics to submit NDA for migalastat for Fabry disease

Teijin Pharma and Amgen report ROR-gamma antagonists

BARDA funding awarded to Crucell Holland to accelerate Ebola vaccine program

Laboratoire Biodim discloses dltA inhibitors

Glenmark Pharmaceuticals' GBR-1302 to enter phase I trials

Ono Pharmaceutical describes EP2 agonists

Jiangsu Ascentage Biomed Development reports ALK inhibitors

Andexanet alfa achieves rapid and sustained reversal of rivaroxaban in phase III trial

Sichuan Haisco Pharmaceutical reports phosphoramidate antivirals

Mylan initiates offer for Perrigo shares, Perrigo tells shareholders to wait

RepliCel starts phase I trial of autologous fibroblast therapy RCS-01

AZTherapies initiates phase III study of ALZT-OP1 for early Alzheimer's disease

Seegene and BD Life Sciences collaborate to develop multiplex molecular diagnostic assays

Bionomics reports data from phase I trial of BNC-210 for anxiety and depression

Depomed urges shareholders to reject Horizon Pharma's unsolicited exchange offer

Hemostemix signs strategic alliance agreement with Hemostemix Asia for ACP-01

Cotranstplantation of islets and dental pulp stem cells improves survival in diabetic mice

ALCAM mediates late kidney complications of diabetes

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
At AACR: Epigenetic fingerprints in metastases track tumor origin
BioWorld
When a tumor migrates and colonizes another tissue or organ, it can be identified as a metastasis, but its origin is not always clear. Now, a study based on...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...